Online ISSN:2583-0376

## Original Article : Open Access

# Exploring the molecular structural requirements of 3, 4, 5-trisubstituted triazoles and imidazotriazole analogues as angiotensin II receptor using molecular modeling approach 

Mukesh Chandra Sharma*<br>School of Pharmacy, Devi Ahilya Vishwavidyalaya, Indore-452001, Madhya Pradesh, India

## Article Info

Article history
Received 8 July 2023
Revised 11 August 2023
Accepted 12 August 2023
Published Online 30 September 2023

## Keywords

Angiotensin II receptor
$k$ nearest neighbor
Pharmacophore
Triazole
Imidazotriazole
Antihypertensive agents


#### Abstract

This work presents the development of a quantitative structure-activity relationship model to predict the antihypertensive activity of 3,4,5-trisubstituted 4H-1,2,4-triazoles and a related series of 3 H -imidazo [1,2b] [1,2,4] triazoles derivatives. These 4H-1,2,4-triazole and 3H-imidazo [1,2-b][1,2,4] triazoles derivatives were divided into a training set of fifty-two compounds and a test set of thirty-three compounds. The best 2D model with multiple linear regressions, giving a square correlation coefficient of 0.8173 , crossvalidated squared correlation coefficient of 0.7524 , and predictable ability of 0.8836 , and the 3D model produced good predictive models with a cross-validated correlation coefficient of 0.7994 and external test set 0.7005 values using the stepwise variable selection $k$-nearest neighbor molecular field analysis approach. The results will serve as a basis for the future design of potent molecules for angiotensin II AT1 receptor for antihypertensive agents.


## 1. Introduction

Angiotensin II is the most important endocrine ligand in the renin angiotensin system (RAS), contributing to the development of several cardiovascular diseases including hypertension (Karnik et al., 2015). The renin-angiotensin-aldosterone system is intricately involved in the pathophysiology of several diseases, including hypertension, congestive heart failure, and chronic kidney disease of all types, including diabetic nephropathy (Hernández-Hernández et al., 2002). The presence of two subtypes of angiotensin II receptors were pharmacologically recognized based on the sensitivity to the first orally active nonpeptide angiotensin II receptor antagonist (Bumpus et al.,1991). Angiotensin II receptor blockers represent a class of effective and well tolerated orally active antihypertensive drugs. Activation of $\mathrm{AT}_{1}$ receptor leads to vasoconstriction, stimulation of the release of catecholamines and antidiuretic hormone and promote growth of vascular and cardiac muscle (Maggioni, 2006). Losartan was the first drug of this class marketed, shortly followed by valsartan, irbesartan, telmisartan, candesartan, eprosartan and others on current investigation. All these drugs have the common properties of blockading the $\mathrm{AT}_{1}$ receptor, thereby relaxing vascular smooth muscle, increase salt excretion, decrease cellular hypertrophy and induce antihypertensive effect without modifying heart rate or cardiac

[^0]Copyright © 2023 Ukaaz Publications. All rights reserved. Email: ukaaz@yahoo.com; Website: www.ukaazpublications.com
output (Cernes et al., 2011). Quantitative structure - activity relationships (QSAR) have come into widespread use for the prediction of various molecular properties and biological responses. The different topological descriptors can be used in place of experimentally derived descriptors in QSARs for prediction of properties (Gute and Basak,1997). The field of computational medicinal chemistry comprises computational approaches for the design, the development and the synthesis of pharmacologically active compounds (Schneider, 2011). QSAR models are essential to optimize the structure that gives the desired biological activities (Hellberg et al., 1987). This approach could predict the biological activity of newly designed derivatives and being made these derivatives should be synthesized and tested. Imidazole moiety is a scaffold that is not only synthetically important but also possesses a wide range of promising biological activities. The series of eighty-five 3,4,5-trisubstituted 4H-1,2,4-triazoles and a related series of 3H-imidazo [1,2-b][1,2,4] triazoles derivatives was used for multiple linear regression model generation using the VLife MDS 3.5 software package. Different 2D physicochemical descriptors were used as independent variables and were correlated with angiotensin II $\mathrm{AT}_{1}$ receptor antagonist's activity. We used the k nearest neighbor and pharmacophore methods to study the relationship of the structure and biological activity, which provide a theoretical basis for the further structural optimization of these compounds. These steric, electrostatic and hydrophobic field descriptors are useful for the better understanding of molecular modeling studies of these series of compounds in terms of ligand-receptor interactions.

Table 1: Structures of triazole and imidazotriazole derivatives and their activity


| S. No. | R | R' | Z | $\mathrm{IC}_{50}{ }^{\text {a }}$ | pIC ${ }_{50}{ }^{\text {b }}$ | Dataset |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | Bu | Ph | COOH | 930 | 6.03 | Training |
| 2 | EtS | Ph | COOH | 1900 | 5.72 | Training |
| 3 | PrS | Ph | COOH | 1600 | 5.79 | Training |
| 4 | Bu | 4-pyridyl | COOH | 1400 | 5.85 | Training |
| 5 | Bu | 3-pyridyl | COOH | 1700 | 5.76 | Test |
| 6 | Bu | 2-furyl | COOH | 1000 | 6.00 | Training |
| 7 | EtS | $\mathrm{CH}_{2} \mathrm{Ph}$ | COOH | 1000 | 6.00 | Training |
| 8 | PrS | $\mathrm{CH}_{2} \mathrm{Ph}$ | COOH | 380 | 6.42 | Test |
| 9 | PrS | $\left(\mathrm{CH}_{2}\right)_{2} \mathrm{Ph}$ | COOH | 75 | 7.12 | Training |
| 10 | PrS | $\left(\mathrm{CH}_{2}\right)_{3} \mathrm{Ph}$ | COOH | 320 | 6.49 | Test |
| 11 | PrS | $\mathrm{CH}_{2} \mathrm{SPh}$ | COOH | 1200 | 5.92 | Training |
| 12 | EtS | $\mathrm{CH}_{2} \mathrm{OMe}$ | COOH | 5200 | 5.28 | Training |
| 13 | EtS | $\mathrm{CF}_{3}$ | COOH | 4800 | 5.31 | Training |
| 14 | PrS | $\mathrm{CF}_{3}$ | COOH | 2100 | 5.67 | Test |
| 15 | Bu | $\mathrm{SCH}_{2} \mathrm{CO}_{2} \mathrm{Me}$ | COOH | 330 | 6.48 | Training |
| 16 | Bu | $\mathrm{SCH}_{2} \mathrm{CONHMe}$ | COOH | 720 | 6.14 | Training |
| 17 | Bu | $\mathrm{SCH}_{2} \mathrm{CO}_{2} \mathrm{H}$ | COOH | 770 | 6.11 | Training |
| 18 | Bu | $\mathrm{S}\left(\mathrm{CH}_{2}\right)_{2} \mathrm{OH}$ | COOH | 480 | 6.31 | Test |
| 19 | Bu | $\mathrm{SCH}(\mathrm{Et}) \mathrm{CO}_{2} \mathrm{Me}$ | COOH | 300 | 6.52 | Test |
| 20 | Bu | $\mathrm{SCH}_{2} \mathrm{COPh}$ | COOH | 190 | 6.72 | Training |
| 21 | Bu | SPh | COOH | 60 | 7.22 | Training |
| 22 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}$ | COOH | 15 | 7.82 | Test |
| 23 | Bu | $\mathrm{S}\left(\mathrm{CH}_{2}\right)_{2} \mathrm{Ph}$ | COOH | 70 | 7.15 | Training |
| 24 | Pr | $\mathrm{SCH}_{2} \mathrm{Ph}$ | COOH | 120 | 6.92 | Test |
| 25 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}(2-\mathrm{Me})$ | COOH | 14 | 7.85 | Training |
| 26 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}(3-\mathrm{Me})$ | COOH | 32 | 7.49 | Test |
| 27 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}(4-\mathrm{Me})$ | COOH | 7.6 | 8.11 | Training |
| 28 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}(2-\mathrm{Cl})$ | COOH | 30 | 7.52 | Test |
| 29 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}(3-\mathrm{Cl})$ | COOH | 26 | 7.58 | Test |
| 30 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}(4-\mathrm{Cl})$ | COOH | 6.8 | 8.16 | Training |
| 31 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}(3-\mathrm{OMe})$ | COOH | 21 | 7.67 | Training |
| 32 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}(4-\mathrm{OMe})$ | COOH | 3 | 8.52 | Test |
| 33 | Bu | $\mathrm{SOCH}_{2} \mathrm{Ph}(4-\mathrm{OMe})$ | COOH | 7.4 | 8.13 | Training |


| 34 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}(2-\mathrm{CN})$ | COOH | 60 | 7.22 | Test |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 35 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}\left(4-\mathrm{CF}_{3}\right)$ | COOH | 42 | 7.37 | Test |
| 36 | Bu | SCH2 (P-naphthyl) | COOH | 49 | 7.30 | Training |
| 37 | Bu | $\mathrm{SCH}\left(\mathrm{CO}_{2} \mathrm{Me}\right) \mathrm{Ph}$ | COOH | 6.1 | 8.21 | Training |
| 38 | Bu | $\mathrm{SCH}\left(\mathrm{CO}_{2} \mathrm{H}\right) \mathrm{Ph}$ | COOH | 20 | 7.69 | Test |
| 39 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}\left(2-\mathrm{CO}_{2} \mathrm{Me}\right)$ | COOH | 14 | 7.85 | Training |
| 40 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}\left(2-\mathrm{CO}_{2} \mathrm{H}\right)$ | COOH | 3.3 | 8.48 | Test |
| 41 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}\left(3-\mathrm{CO}_{2} \mathrm{Me}\right)$ | COOH | 30 | 7.52 | Training |
| 42 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}\left(3-\mathrm{CO}_{2} \mathrm{H}\right)$ | COOH | 15 | 7.82 | Training |
| 43 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}(4-\mathrm{C} 1)$ | $\mathrm{CN}_{4} \mathrm{H}$ | 6.8 | 8.16 | Test |
| 44 | Bu | $\mathrm{SCH}_{2} \mathrm{Ph}(4-\mathrm{OMe})$ | $\mathrm{CN}_{4} \mathrm{H}$ | 4.1 | 8.38 | Test |
| 45 | Bu | $\mathrm{SOCH}_{2} \mathrm{Ph}(4-\mathrm{C} 1)$ | $\mathrm{CN}_{4} \mathrm{H}$ | 33 | 7.48 | Training |
| 46 | Bu | $\mathrm{SOCH}_{2} \mathrm{Ph}(4-\mathrm{OMe})$ | $\mathrm{CN}_{4} \mathrm{H}$ | 28 | 7.55 | Training |
|  | R | Z |  |  |  |  |
| 47 | H | $\mathrm{SCH}_{2} \mathrm{CO}_{2} \mathrm{Me}$ | COOH | 540 | 6.26 | Training |
| 48 | H | SH | COOH | 860 | 6.06 | Test |
| 49 | H | $\mathrm{SCMe}_{3}$ | COOH | 890 | 6.05 | Training |
| 50 | H | SMe | $\mathrm{CN}_{4} \mathrm{H}$ | 310 | 6.50 | Training |
| 51 | H | $\mathrm{SCH}_{2} \mathrm{CHMe}_{2}$ | $\mathrm{CN}_{4} \mathrm{H}$ | 72 | 7.14 | Test |
| 52 | H | $\mathrm{SCH}_{2}$-Cyclohexyl | $\mathrm{CN}_{4} \mathrm{H}$ | 36 | 7.44 | Training |
| 53 | H | SPh | $\mathrm{CN}_{4} \mathrm{H}$ | 100 | 7.00 | Training |
| 54 | H | $\mathrm{SCH}_{2} \mathrm{Ph}$ | $\mathrm{CN}_{4} \mathrm{H}$ | 7.1 | 8.14 | Test |
| 55 | H | $\mathrm{S}\left(\mathrm{CH}_{2}\right)_{2} \mathrm{Ph}$ | $\mathrm{CN}_{4} \mathrm{H}$ | 35 | 7.45 | Training |
| 56 | H | $\mathrm{SCH}_{2} \mathrm{Ph}(2-\mathrm{Me})$ | $\mathrm{CN}_{4} \mathrm{H}$ | 17 | 7.76 | Training |
| 57 | H | $\mathrm{SCH}_{2} \mathrm{Ph}(2-\mathrm{Cl})$ | $\mathrm{CN}_{4} \mathrm{H}$ | 110 | 6.95 | Test |
| 58 | H | $\mathrm{SCH}_{2} \mathrm{Ph}(4-\mathrm{Cl})$ | $\mathrm{CN}_{4} \mathrm{H}$ | 98 | 7.008 | Training |
| 59 | H | $\mathrm{SCH}_{2} \mathrm{Ph}(4-\mathrm{Cl})$ | $\mathrm{CN}_{4} \mathrm{H}$ | 24 | 7.61 | Test |
| 60 | H | $\mathrm{SCH}_{2} \mathrm{Ph}(4-\mathrm{Cl})$ | $\mathrm{CN}_{4} \mathrm{H}$ | 94 | 7.02 | Training |
| 61 | H | SCH2 $\mathrm{Ph}\left(2-\mathrm{NO}_{2}\right)$ | $\mathrm{CN}_{4} \mathrm{H}$ | 130 | 6.88 | Test |
| 62 | H | SCH2 $\mathrm{Ph}\left(4-\mathrm{NO}_{2}\right)$ | $\mathrm{CN}_{4} \mathrm{H}$ | 6.6 | 8.18 | Training |
| 63 | H | $\mathrm{SCH}_{2} \mathrm{Ph}(3-\mathrm{OMe})$ | $\mathrm{CN}_{4} \mathrm{H}$ | 94 | 7.02 | Test |
| 64 | H | $\mathrm{SCH}_{2} \mathrm{Ph}(4-\mathrm{OMe})$ | $\mathrm{CN}_{4} \mathrm{H}$ | 31 | 7.50 | Training |
| 65 | H | $\mathrm{SCH}_{2} \mathrm{Ph}\left(4-\mathrm{CO}_{2} \mathrm{Me}\right)$ | $\mathrm{CN}_{4} \mathrm{H}$ | 120 | 6.92 | Training |
| 66 | H | $\mathrm{SCH}_{2} \mathrm{Ph}\left(4-\mathrm{CO}_{2} \mathrm{H}\right)$ | $\mathrm{CN}_{4} \mathrm{H}$ | 24 | 7.61 | Test |
| 67 | H | $\mathrm{SCH}_{2} \mathrm{Ph}\left(2-\mathrm{CO}_{2} \mathrm{Me}\right)$ | $\mathrm{CN}_{4} \mathrm{H}$ | 90 | 7.04 | Training |
| 68 | H | $\mathrm{SCH}_{2} \mathrm{Ph}\left(2-\mathrm{CO}_{2} \mathrm{H}\right)$ | $\mathrm{CN}_{4} \mathrm{H}$ | 1.5 | 8.82 | Test |
| 69 | H | $\mathrm{SCH}_{2} \mathrm{Ph}\left(2-\mathrm{CH}_{2} \mathrm{OH}\right)$ | $\mathrm{CN}_{4} \mathrm{H}$ | 36 | 7.44 | Training |
| 70 | H | $\mathrm{SCH}_{2} \mathrm{Ph}\left(2-\mathrm{CN}_{4} \mathrm{H}\right)$ | $\mathrm{CN}_{4} \mathrm{H}$ | 1.4 | 8.85 | Test |
| 71 | H | $\mathrm{SO}_{2} \mathrm{Me}$ | $\mathrm{CN}_{4} \mathrm{H}$ | 400 | 6.39 | Training |
| 72 | H | $\mathrm{SOCH}_{2} \mathrm{Ph}(4-\mathrm{Cl})$ | $\mathrm{CN}_{4} \mathrm{H}$ | 11 | 7.95 | Test |
| 73 | H | $\mathrm{SO}_{2} \mathrm{CH}_{2} \mathrm{Ph}(4-\mathrm{Cl})$ | $\mathrm{CN}_{4} \mathrm{H}$ | 48 | 7.31 | Training |


| 74 | H | $\mathrm{SOCH}_{2} \mathrm{Ph}\left(4-\mathrm{NO}_{2}\right)$ | $\mathrm{CN}_{4} \mathrm{H}$ | 8.9 | 8.05 | Training |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| 75 | H | $\mathrm{SOCH}_{2} \mathrm{Ph}(4-\mathrm{OMe})$ | $\mathrm{CN}_{4} \mathrm{H}$ | 50 | 7.30 | Test |
| 76 | H | $\mathrm{SOCH}_{2} \mathrm{Ph}\left(2-\mathrm{CO}_{2} \mathrm{Me}\right)$ | $\mathrm{CN}_{4} \mathrm{H}$ | 40 | 7.39 | Training |
| 77 | H | $\mathrm{SOCH}_{2} \mathrm{Ph}\left(2-\mathrm{CO}_{2} \mathrm{H}\right)$ | $\mathrm{CN}_{4} \mathrm{H}$ | 10 | 8.00 | Test |
| 78 | H | $\mathrm{OCH}_{2} \mathrm{Ph}$ | $\mathrm{CN}_{4} \mathrm{H}$ | 370 | 6.43 | Training |
| 79 | H | $\left.\mathrm{O}_{4} \mathrm{CH}_{2}\right)_{2} \mathrm{Ph}$ | $\mathrm{CN}_{4} \mathrm{H}$ | 63 | 7.20 | Test |
| 80 | H | $\mathrm{NHCH}_{2} \mathrm{Ph}$ | $\mathrm{CN}_{4} \mathrm{H}$ | 28 | 7.55 | Training |
| 81 | H | $\mathrm{NHCH}_{2} \mathrm{Ph}(4-\mathrm{Cl})$ | $\mathrm{CN}_{4} \mathrm{H}$ | 140 | 6.85 | Training |
| 82 | H | $\mathrm{NHCH}_{2} \mathrm{Ph}(4-\mathrm{OMe})$ | $\mathrm{CN}_{4} \mathrm{H}$ | 780 | 6.10 | Test |
| 83 | H | $\mathrm{CONHCH}_{2} \mathrm{Ph}$ | $\mathrm{CN}_{4} \mathrm{H}$ | 89 | 7.24 | Training |
| 84 | H | $\left.\mathrm{CON}_{4} \mathrm{Me}\right) \mathrm{CH} \mathrm{Hh}_{2}$ | 7.05 | Training |  |  |
| 85 | H | $\mathrm{CON(Me)Ph}$ | 350 | 6.45 | Training |  |

${ }^{\mathrm{a}} \mathrm{IC} 50$ or inhibition of specific binding of $\left[{ }^{125} \mathrm{I}\right]$ Ang II AT ${ }_{1}$ receptor rabbit aorta, ${ }^{\mathrm{b}}-\log \mathrm{IC}_{50}$ to generate equation.

## 2. Materials and Methods

In this work, the dataset of the activities of eighty-five compounds were selected from the synthesized series of 3,4,5-trisubstituted $4 \mathrm{H}-1,2,4$-triazoles and 3 H -imidazo[1,2-b][1,2,4] triazole as angiotensin II $\mathrm{AT}_{1}$ receptor antagonists (Ashton et al.,1993). The molecular structures of the studied molecules with their activity for eighty-five derivatives are presented in Table 1. All experimental activity values $\mathrm{IC}_{50}$ were converted to $\mathrm{pIC}_{50} .2 \mathrm{D}$ structures of all the eighty-five compounds were sketched and converted into 3D structures using VLife molecular design suite software package (VLife MDS, 2010). The training set comprises fifty-two compounds and the test set consists of thirty-three compounds (Golbraikh and Tropsha, 2002). The minimization was terminated when the distance dependent dielectric constant of 1.0 and the convergence criterion of $0.01 \mathrm{kcal} / \mathrm{mol} \AA$ (Halgren, 1996). A large number of theoretical 2D individual descriptors such as molar refractivity, molecular weight, partition coefficient, volume, estate numbers, polar surface area, element count, dipole moment have been computed. The physicochemical descriptors include 239 physicochemical parameters, 700 alignment type parameters and 99 atom type count descriptors were calculated. Energy minimized structures of molecules were aligned by the template-based method (Ajmani et al., 2006). The template structure imidazotriazole ring is shown in Figure 1. The alignment of all molecules is shown in Figure 2.


Figure 1: Stereo view of the template.


Figure 2: Stereo view of the alignment of the dataset.
The position of each atom is important for k nearest neighbor study because the descriptors calculation is based on the 3D space grid. To derive the k nearest neighbor molecular field analysis descriptor fields, a 3D cubic lattice with grid spacing of $2 \AA$ in $x, y$, and $z$ dimensions was created to encompass the aligned molecules. The descriptors were calculated using a sp3 carbon probe atom with a van der Waals radius of $1.52 \AA$ and a charge of +1.0 with a default cut-off energy value of $\pm 30 \mathrm{kcal} / \mathrm{mol}$ to generate steric, electrostatic and hydrophobic fields. The steric, electrostatic and hydrophobic energy values were truncated at a default value of $\pm 30 \mathrm{kcal} / \mathrm{mol}$ (Clark et al., 1989). This resulted in the calculation of 4500 field descriptors ( 1500 for each electrostatic, steric and hydrophobic) for all the compounds in separate columns. The pharmacophore model was developed using the MolSign module of VLife molecular design suite. The pharmacophore model consisting of a set of threedimensional attributes essential for the bioactive ligand was generated using a minimum of four pharmacophoric features, $10 \AA$ as the tolerance limit and $30 \AA$ as the maximum allowed distance (Sharma et al., 2014; Sharma, 2015).

Table 2: Unicolumn statistics of activity for training and test set compounds

| Dataset | Average | Max. | Min. | Std.Dev | Su m |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |
| 2D- QSAR |  |  |  |  |  |  |
| Training | 11.783 | 16.322 | 5.278 | 0.971 | 144.58 |  |
| Test | 9.680 | 7.2788 | 3.176 | 0.895 | 59.48 |  |
| 3D-QSAR |  |  |  |  |  |  |
| Training | 16.216 | 19.187 | 7.321 | 1.785 | 185.31 |  |
| Test | 12.873 | 10.965 | 6.017 | 1.154 | 74.32 |  |

## 3. Results

In the present study, partial least squares applied with stepwise variable selection method was used to develop 2D and 3D QSAR models of 3,4,5-trisubstituted 4H-1,2,4-triazoles derivatives based on steric, electrostatic and hydrophobic fields. Statistical measures used for the evaluation of models were the number of compounds in the regression coefficient $\mathrm{r}^{2}$, the F-test (Fischer's value) for statistical significance F , the cross-validated correlation coefficient $\mathrm{q}^{2}$ and the standard error of estimation $\mathrm{r}^{2}$ and $\mathrm{q}^{2}$. The F-test reflects the ratio of the variance explained by the model and the variance due to the error in the regression. Predicted squared regression (pred_r${ }^{2}$ ) and standard error of predicted squared regression (pred_ $\mathrm{r}^{2} \mathrm{se}$ ) to estimate the predictive potential of the models respectively, standard error ( $\mathrm{r}^{2}$ _se) representing absolute measure of quality of fit, and standard error of cross-validated square correlation coefficient ( $\mathrm{q}^{2}$ _se). A value of
$\mathrm{r}^{2}$ pred greater than 0.5 indicates the good predictive capacity of the model. A uni column statistics for training set and test set were generated to check correctness of selection criteria for trainings and test set molecules (Table 2). The frequency of use of a particular descriptor in the population of equations indicated the relevant contributions of the descriptors (Table 3). Model-1 shows good squared correlation coefficient $\left(\mathrm{r}^{2}\right)$ of 0.8173 explains $81 \%$ variance in biological activity. The low standard error of $r^{2}$ _se 0.3117 demonstrates accuracy of the model. The F test value of 61.487 shows the overall statistical significance level to be $99.99 \%$ of the model. Cross validated squared correlation coefficient of this model was 0.7524 , which shows the good internal prediction power of this model. Another parameter for predictivity of test set compound is high pred_r $r^{2} 0.7813$ and low pred_ $r^{2}$ se 0.6431 , which is showing good external predictive power of the model. The plots of observed activity vs predicted activity values of $\mathrm{pIC}_{50}$ are shown in Figure 3.


Figure 3: Relation between observed versus predicted activity for 2D model 1.

Model-2 shows good squared correlation coefficient ( $\left(^{2}\right.$ ) of 0.7819 explains $78 \%$ variance in biological activity. The low standard error of $\mathrm{r}^{2}$ _se 0.3799 demonstrates accuracy of the model. This model also indicates statistical significance $99.9 \%$ with F values 77.32 . Cross validated squared correlation coefficient of this model was 0.7014 , which shows the good internal prediction power of this model. Another parameter for predictivity of test set compound is
high pred_r $r^{2} 0.7539$ and low pred_ $r^{2}$ se 0.6825 , which is showing good external predictive power of the model. The 3D QSAR model3 showed significant correlation coefficient $q^{2}$ of 0.7994 , standard error of predicted squared regression of $0.3952, \mathrm{r}^{2}$ for external test set 0.7360 , degree of freedom 33 and $k$ nearest neighbour of 4 and external predictability of the model using the test set was determined by pred_r ${ }^{2}$, which is 0.7005 . The points generated in 3D QSAR model 3 are $\mathrm{S}_{-} 735,-\mathrm{S}_{-} 1130$, E_912 and H_1007 that is, steric,
electrostatic and hydrophobic interaction respectively (Figure 4). The plots of observed activity vs predicted activity values of $\mathrm{pIC}_{50}$ are shown in Figure 5. Model 4 was found to be statistically most significant, especially with respect to the internal predictive ability 0.7251 of the model. 3D QSAR models were selected based on value of statistical parameters and the best 3D QSAR models have a $q^{2}$ _se of 0.4192 and pred_r $r^{2}$ of 0.6831 . The points generated in 3D QSAR model 4 are S_498, E_790, E_1005 and H_1236 that is, steric,
electrostatic and hydrophobic interaction respectively (Figure 6). The pharmacophore model was built using the Molsign module of VLife MDS. For five-point pharmacophore identification tolerance limit set up to $20 \AA$ and max distance allowed between two features, set the value to $5 \AA$. This model, containing chemical functionalities such as hydrogen bond donor, hydrogen bond acceptor, hydrophobic, aliphatic, negative ionisable, positive ionizable and aromatic carbon centre can serve as an effective search filter for virtual screening.

Table 3: Statistical parameters of models

| 2D Model-1 | $\mathrm{pIC}_{50}=-0.7695( \pm 0.3440)$ Polar surface area (Including sulfur atom) $-0.1662( \pm 0.0363) \mathrm{T} \_2 \_\mathrm{F} \_4+0.4752( \pm 0.1829)$ $T_{-} \mathrm{C}_{2} \mathrm{O}_{-} 1+0.2606( \pm 0.1448)$ H-donor countOptimum Components $=5, \mathrm{~N}_{\text {Training }}=52, \mathrm{~N}_{\text {Test }}=33, \mathrm{r}^{2}=0.8173, \mathrm{q}^{2}=$ $0.7524, \mathrm{~F}$ test $=61.487, \mathrm{r}^{2}{ }_{-} \mathrm{se}=0.311, \mathrm{q}^{2} \_\mathrm{se}=0.643$, pred_r $\mathrm{r}^{2}=0.7813$, pred_r $\mathrm{r}^{2} \mathrm{se}=0.6431$. |
| :---: | :---: |
| 2D Model-2 | $\mathrm{pIC}_{50}=0.3585( \pm 0.0493)$ 5ChainCount- $0.4984( \pm 0.2319)$ T_O_S_6-0.9598 ( $\pm 0.6402$ ) T_S_Cl_6+ 0.2076( $\pm 0.0243$ ) $T_{-} C_{-} S_{-2 O p t i m u m ~ C o m p o n e n t s ~}=5, \mathrm{~N}_{\text {Training }}=52, \mathrm{~N}_{\text {Test }}=33, \mathrm{r}^{2}=0.7819, \mathrm{q}^{2}=0.7014, \mathrm{~F}$ test $=77.32, \mathrm{r}^{2}{ }^{2} \mathrm{se}=0.564, \mathrm{q}^{2}$ $\mathrm{se}=0.643$, pred_r $\mathrm{r}^{2}=0.7539$, pred_r ${ }^{2} \mathrm{se}=0.682$. |
| 3D Model-3 | $\begin{aligned} & \text { pIC50 }=-1.7695+\mathrm{H}_{-} 1007(0.3705,0.4404)+\mathrm{E}_{-} 912(2.0154,2.1266)+\mathrm{S}-735 \quad(-0.6671,3.1985)-\mathrm{S}_{-} 1130(30.0000 \\ & 30.0000) \mathrm{k} \text { Nearest Neighbour }=4 ; \mathrm{N}_{\text {Training }}=52, \mathrm{~N} \underset{\text { Test }}{ }=33 \text {, Optimum Components }=4, \mathrm{DF}=33, \mathrm{q}^{2}=0.7994, \mathrm{q}^{2}{ }_{-} \text {se } \\ & =0.2306 \text {, pred_r } \mathrm{r}^{2}=0.7005 \text {, pred_r }{ }^{2} \mathrm{se}=0.3952 \end{aligned}$ |
| 3D Model-4 | pIC50 $=0.5138-$ E_790 ( $-1.8662, \quad-0.9458)-$ E_1005 $^{(-1.2756,-0.0455)}+$ H_1 $^{2} 1236(0.1093, \quad 0.4918)-$ S_498 $(-0.5820 \quad,-0.2431) \mathrm{k}$ Nearest Neighbour $=4 ; \mathrm{N}_{\text {Training }}=52, \mathrm{~N}_{\text {Test }}=33$, Optimum Components $=4, \mathrm{DF}=31, \mathrm{q}^{2}=$ $0.725, \mathrm{~F}$ test $=51.37, \mathrm{q}^{2}$ _se $=0.419$, pred_r $\mathrm{r}^{2}=0.6831$, pred_r $\mathrm{r}^{2} \mathrm{se}=0.642$ |



Figure 4: Contribution plot of steric, electrostatic field and hydrophobic interactions 3D model 3.
Table 4: Observed activities and predicted activities of compounds by models

| Comp. | $\mathrm{pIC}_{50}$ | 2D-Model-1 |  | 2D-Model-2 |  | 3D Model-3 |  | 3D Model-4 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Pred. | Res. | Pred. | Res. | Pred. | Res. | Pred. | Res. |
| 1 | 6.03 | 5.7925 | 0.2375 | 5.6961 | 0.3339 | 6.3029 | -0.2729 | 6.1815 | -0.1515 |
| 2 | 5.72 | 5.3215 | 0.3985 | 5.9012 | -0.1812 | 5.8989 | -0.1789 | 5.6776 | 0.0424 |
| 3 | 5.79 | 5.4423 | 0.3477 | 5.3022 | 0.4878 | 5.9973 | -0.2073 | 5.2945 | 0.4955 |
| 4 | 5.85 | 6.1466 | -0.2966 | 5.6301 | 0.2199 | 6.0223 | -0.1723 | 5.6921 | 0.1579 |
| 5 | 5.76 | 5.3463 | 0.4137 | 5.2826 | 0.4774 | 5.3218 | 0.4382 | 5.4689 | 0.2911 |
| 6 | 6.00 | 5.6488 | 0.3512 | 5.7606 | 0.2394 | 6.3063 | -0.3063 | 5.6853 | 0.3147 |
| 7 | 6.00 | 5.5331 | 0.4669 | 5.6847 | 0.3153 | 6.4062 | -0.4062 | 5.7793 | 0.2207 |


| 8 | 6.42 | 6.1845 | 0.2355 | 6.5732 | -0.1532 | 6.2011 | 0.2189 | 6.0708 | 0.3492 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 9 | 7.12 | 6.8776 | 0.2424 | 7.3802 | -0.2602 | 6.8571 | 0.2629 | 6.9356 | 0.1844 |
| 10 | 6.49 | 6.2154 | 0.2746 | 6.6196 | -0.1296 | 6.1901 | 0.2999 | 6.3056 | 0.1844 |
| 11 | 5.92 | 6.1799 | -0.2599 | 5.7156 | 0.2044 | 6.0917 | -0.1717 | 5.6258 | 0.2942 |
| 12 | 5.28 | 4.9227 | 0.3573 | 4.9955 | 0.2845 | 5.0119 | 0.2681 | 5.1998 | 0.0802 |
| 13 | 5.31 | 5.5952 | -0.2852 | 5.3562 | -0.0462 | 5.1383 | 0.1717 | 5.3134 | -0.0034 |
| 14 | 5.67 | 6.0101 | -0.3401 | 5.3124 | 0.3576 | 5.3808 | 0.2892 | 5.2604 | 0.4096 |
| 15 | 6.48 | 6.7994 | -0.3194 | 6.7297 | -0.2497 | 6.6701 | -0.1901 | 6.2732 | 0.2068 |
| 16 | 6.14 | 5.8473 | 0.2927 | 5.9357 | 0.2043 | 6.0261 | 0.1139 | 6.2671 | -0.1271 |
| 17 | 6.11 | 6.2862 | -0.1762 | 5.7751 | 0.3349 | 6.3948 | -0.2848 | 5.8628 | 0.2472 |
| 18 | 6.31 | 5.9904 | 0.3196 | 5.4856 | 0.8244 | 6.4782 | -0.1682 | 6.1662 | 0.1438 |
| 19 | 6.52 | 6.7805 | -0.2605 | 6.6544 | -0.1344 | 6.3489 | 0.1711 | 6.2203 | 0.2997 |
| 20 | 6.72 | 7.0852 | -0.3652 | 6.4218 | 0.2982 | 6.4565 | 0.2635 | 6.3303 | 0.3897 |
| 21 | 7.22 | 7.5456 | -0.3256 | 7.3584 | -0.1384 | 6.9308 | 0.2892 | 6.8176 | 0.4024 |
| 22 | 7.82 | 8.1674 | -0.3474 | 7.6536 | 0.1664 | 7.5572 | 0.2628 | 7.4958 | 0.3242 |
| 23 | 7.15 | 7.3296 | -0.1796 | 6.7891 | 0.3609 | 6.9068 | 0.2432 | 6.8371 | 0.3129 |
| 24 | 6.92 | 6.6097 | 0.3103 | 7.2194 | -0.2994 | 6.7181 | 0.2019 | 6.6458 | 0.2742 |
| 25 | 7.85 | 8.2375 | -0.3875 | 7.5602 | 0.2898 | 7.5128 | 0.3372 | 7.6949 | 0.1551 |
| 26 | 7.49 | 7.6951 | -0.2051 | 7.3893 | 0.1007 | 7.2838 | 0.2062 | 7.2018 | 0.2882 |
| 27 | 8.11 | 8.3844 | -0.2744 | 7.9782 | 0.1318 | 7.8735 | 0.2365 | 8.2619 | -0.1519 |
| 28 | 7.52 | 7.3673 | 0.1527 | 7.0217 | 0.4983 | 7.2429 | 0.2771 | 7.1141 | 0.4059 |
| 29 | 7.58 | 7.1705 | 0.4095 | 7.4491 | 0.1309 | 7.2503 | 0.3297 | 7.2398 | 0.3402 |
| 30 | 8.16 | 8.4675 | -0.3075 | 8.3191 | -0.1591 | 8.0572 | 0.1028 | 7.9463 | 0.2137 |
| 31 | 7.67 | 7.3876 | 0.2824 | 7.4654 | 0.2046 | 7.2835 | 0.3865 | 7.1995 | 0.4705 |
| 32 | 8.52 | 8.8265 | -0.3065 | 8.3275 | 0.1925 | 8.2762 | 0.2438 | 8.1972 | 0.3228 |
| 33 | 8.13 | 7.8847 | 0.2453 | 8.3088 | -0.1788 | 7.9648 | 0.1652 | 8.2462 | -0.1162 |
| 34 | 7.22 | 6.9448 | 0.2752 | 7.3879 | -0.1679 | 6.8607 | 0.3593 | 7.0176 | 0.2024 |
| 35 | 7.37 | 7.6237 | -0.2537 | 7.0416 | 0.3284 | 7.5473 | -0.1773 | 7.1223 | 0.2477 |
| 36 | 7.30 | 7.1571 | 0.1429 | 7.3885 | -0.0885 | 7.0121 | 0.2879 | 7.5958 | -0.2958 |
| 37 | 8.21 | 8.4584 | -0.2484 | 7.9764 | 0.2336 | 8.3623 | -0.1523 | 8.0983 | 0.1117 |
| 38 | 7.69 | 7.4557 | 0.2343 | 7.7215 | -0.0315 | 7.2604 | 0.4296 | 7.5069 | 0.1831 |
| 39 | 7.85 | 8.1162 | -0.2662 | 7.4981 | 0.3519 | 7.6946 | 0.1554 | 7.5742 | 0.2758 |
| 40 | 8.48 | 8.7016 | -0.2216 | 8.6986 | -0.2186 | 8.1957 | 0.2843 | 8.2958 | 0.1842 |
| 41 | 7.52 | 7.1742 | 0.3458 | 7.0669 | 0.4531 | 7.2482 | 0.2718 | 7.3595 | 0.1605 |
| 42 | 7.82 | 7.5522 | 0.2678 | 8.1854 | -0.3654 | 7.6159 | 0.2041 | 7.4473 | 0.3727 |
| 43 | 8.16 | 7.9366 | 0.2234 | 8.0325 | 0.1275 | 8.3492 | -0.1892 | 7.8583 | 0.3017 |
| 44 | 8.38 | 8.5755 | -0.1955 | 8.6972 | -0.3172 | 8.2142 | 0.1658 | 8.1916 | 0.1884 |
| 45 | 7.48 | 7.1766 | 0.3034 | 7.6538 | -0.1738 | 7.6853 | -0.2053 | 7.1918 | 0.2882 |
| 46 | 7.55 | 7.2338 | 0.3162 | 7.7146 | -0.1646 | 7.1148 | 0.4352 | 7.3425 | 0.2075 |
| 47 | 6.26 | 6.4763 | -0.2163 | 6.3378 | -0.0778 | 5.9942 | 0.2658 | 6.0594 | 0.2006 |
| 48 | 6.06 | 5.6985 | 0.3615 | 6.1169 | -0.0569 | 6.1869 | -0.1269 | 6.0948 | -0.0348 |
| 49 | 6.05 | 6.2759 | -0.2259 | 5.8675 | 0.1825 | 6.1093 | -0.0593 | 6.2276 | -0.1776 |


| 50 | 6.50 | 6.7042 | -0.2042 | 6.3294 | 0.1706 | 6.5849 | -0.0849 | 6.4127 | 0.0873 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 51 | 7.14 | 7.2258 | -0.0858 | 6.8511 | 0.2889 | 6.9861 | 0.1539 | 7.1882 | -0.0482 |
| 52 | 7.44 | 7.6931 | -0.2531 | 7.5018 | -0.0618 | 7.3079 | 0.1321 | 7. 3362 | 0.1038 |
| 53 | 7.00 | 6.8642 | 0.1358 | 7.1365 | -0.1365 | 6.9883 | 0.0117 | 7.0983 | -0.0983 |
| 54 | 8.14 | 7.8321 | 0.3079 | 7.8524 | 0.2876 | 8.1965 | -0.0565 | 8.0157 | 0.1243 |
| 55 | 7.45 | 7.316 | 0.134 | 7.3943 | 0.0557 | 7.6304 | -0.1804 | 7.7286 | -0.2786 |
| 56 | 7.76 | 7.9416 | -0.1816 | 7.8194 | -0.0594 | 7.8477 | -0.0877 | 7.8207 | -0.0607 |
| 57 | 6.95 | 7.1951 | -0.2451 | 7.0568 | -0.1068 | 6.7643 | 0.1857 | 6.7453 | 0.2047 |
| 58 | 7.008 | 6.7816 | 0.2264 | 7.1413 | -0.1333 | 7.2891 | -0.2811 | 6.7193 | 0.2887 |
| 59 | 7.61 | 7.8841 | -0.2741 | 7.8285 | -0.2185 | 7.8519 | -0.2419 | 7.5335 | 0.0765 |
| 60 | 7.02 | 7.1968 | -0.1768 | 6.9649 | 0.0551 | 6.7834 | 0.2366 | 6.8974 | 0.1226 |
| 61 | 6.88 | 6.6941 | 0.1859 | 6.6897 | 0.1903 | 6.9938 | -0.1138 | 6.8392 | 0.0408 |
| 62 | 8.18 | 8.4481 | -0.2681 | 8.2681 | -0.0881 | 8.2479 | -0.0679 | 7.9844 | 0.1956 |
| 63 | 7.02 | 7.3174 | -0.2974 | 6.7173 | 0.3027 | 6.9394 | 0.0806 | 7.0935 | -0.0735 |
| 64 | 7.50 | 7.5762 | -0.0762 | 7.6285 | -0.1285 | 7.4291 | 0.0709 | 7.5482 | -0.0482 |
| 65 | 6.92 | 7.1287 | -0.2087 | 6.8913 | 0.0287 | 6.8189 | 0.1011 | 7.1433 | -0.2233 |
| 66 | 7.61 | 7.5418 | 0.0682 | 7.8244 | -0.2144 | 7.6988 | -0.0888 | 7.6514 | -0.0414 |
| 67 | 7.04 | 6.8809 | 0.1591 | 6.915 | 0.125 | 7.1291 | -0.0891 | 6.7719 | 0.2681 |
| 68 | 8.82 | 9.0659 | -0.2459 | 8.7448 | 0.0752 | 8.9756 | -0.1556 | 8.6823 | 0.1377 |
| 69 | 7.44 | 7.2751 | 0.1649 | 7. 5502 | -0.1102 | 7.5879 | -0.1479 | 7.2789 | 0.1611 |
| 70 | 8.85 | 8.6831 | 0.1669 | 9.1429 | -0.2929 | 8.6476 | 0.2024 | 8.9873 | -0.1373 |
| 72 | 6.39 | 6.2574 | 0.1326 | 6.1882 | 0.2018 | 6.4514 | -0.0614 | 6.5321 | -0.1421 |
| 72 | 7.95 | 8.1056 | -0.1556 | 7.7462 | 0.2038 | 7.6063 | 0.3437 | 7.8649 | 0.0851 |
| 73 | 7.31 | 7.3879 | -0.0779 | 7.4577 | -0.1477 | 7.4865 | -0.1765 | 7.1309 | 0.1791 |
| 74 | 8.05 | 8.2216 | -0.1716 | 8.1497 | -0.0997 | 7.9468 | 0.1032 | 8.1635 | -0.1135 |
| 75 | 7.30 | 7.1896 | 0.1104 | 7.5725 | -0.2725 | 7.5971 | -0.2971 | 7.1607 | 0.1393 |
| 76 | 7.39 | 7.4879 | -0.0979 | 7.2905 | 0.0995 | 7.1789 | 0.2111 | 7. 2063 | 0.1837 |
| 77 | 8.00 | 8.2147 | -0.2147 | 8.1974 | -0.1974 | 8.1582 | -0.1582 | 6.8326 | 1.1674 |
| 78 | 6.43 | 6.2968 | 0.1332 | 6.6485 | -0.2185 | 6.8546 | -0.4246 | 6.1912 | 0.2388 |
| 79 | 7.20 | 7.1176 | 0.0824 | 6.9829 | 0.2171 | 7.4096 | -0.2096 | 7.6264 | -0.4264 |
| 80 | 7.55 | 7.4968 | 0.0532 | 7.2665 | 0.2835 | 7.4271 | 0.1229 | 7.3213 | 0.2287 |
| 81 | 6.85 | 7.0143 | -0.1643 | 6.7253 | 0.1247 | 6.9385 | -0.0885 | 7.11738 | -0.267 |
| 82 | 6.10 | 5.9683 | 0.1317 | 5.9581 | 0.1419 | 5.8427 | 0.2573 | 6.1639 | -0.0639 |
| 83 | 7.24 | 7.1958 | 0.0442 | 7.3252 | -0.0852 | 7.0415 | 0.1985 | 7.2997 | -0.0597 |
| 84 | 7.05 | 6.9085 | 0.1415 | 7.1892 | -0.1392 | 7.1649 | -0.1149 | 6.8153 | 0.2347 |
| 85 | 6.45 | 6.5493 | -0.0993 | 6.3271 | 0.1229 | 6.6861 | -0.2361 | 6.2876 | 0.1624 |

## 4. Discussion

The derived Model-1 shows good correlation between biological activity and parameters polar surface area, T_2_F_4, T_C_O_1 and $H$ donor count as the correlation coefficient 0.87 and the model explains about $87 \%$ variance in activity. Model- 1 also shows a positive correlation with polar surface area (including sulfur atom), T_C_O_1, and H donor count and a negative correlation with T_2_F_4. As a positive contributing descriptor, polar surface area (including sulfur atom) is an signifies total polar surface area including sulphur plays a most important role in determining activity and descriptor signifies the total polar surface area including sulphur in postion imidazo and triazoles $\mathrm{R}^{!}$and Z . This suggests that substituents such as -SPhCl ,$\mathrm{SCH}_{2} \mathrm{Ph}(-\mathrm{OMe})$ and $\mathrm{SCH}_{2} \mathrm{Ph}\left(-\mathrm{CF}_{3}\right)$ would increase the activity. The
descriptor influencing activity $\mathrm{T}_{-} 2_{-} \mathrm{F} \_4$ is directly proportional to the activity and indicates that increase in the count of number of double bounded atoms (any double bonded atom, T_2) separated from fluorine atom by four bonds in a molecule will lead to positive effect on the activity. The other descriptor T_C_O_1 are inversely proportional which indicates that the presence of methoxy, ethoxy and carbonyl increase in the number of bonds between two carbon atoms at the part $\mathrm{R}, \mathrm{R}^{!}$and Z position end may be detrimental for biological activities. The positive correlation of polar surface area including sulfur atom shows that polar groups like hydroxyl and methoxy at R ! are important for activity. Its positive contribution shows a detrimental effect of an R and $\mathrm{R}^{!}$methyl group on activity. The predicted activities of the compounds by the above model are shown in Table 4.


Figure 5: Comparison of observed activity versus predicted activity for 3D Model-3.

Model-2 also shows with descriptor 5 Chain Count is a number of five membered compounds in a ring, like imidazole and tetrazole variant substituents in triazole is conducive to activity. The tetrazole group in the biphenyl portion role in biological activity of compounds. The descriptor T_C_S_2 count of number of double bounded atoms (i.e., any double bonded atom, T_2) separated from any other double bonded atom by 2 bonds in a molecule in favour increase activity R position of ring. The positive contribution of descriptor T_S_Cl_6 number of sulphur atoms separated from chlorine atom by six bond distance in a molecule and show that presence of sulphur group $1,2,4$-triazole such as compound number 28,29 and 30 position is enhanced for the activity. The positive contribution of next important alignment independent descriptor T_O_S_6 count of number of oxygen atoms (single double or triple bonded) separated from sulphur atom by six bond distance in a molecule position of $4 \mathrm{H}-1,2$, 4triazole is favourable for the activity. The stepwise variable selection method resulted in significant 3D Model-3 and Model-4. The model- 3 shows steric descriptors S_735 (-0.6671,3.1985) showed that negative steric potential is favourable for activity, and less bulky substituents group should be considered in that position at R2 position. The electrostatic data point generated was E_912 (2.0154,2.1266) electropositive groups like methyl, ethyl and butyl group for activity. The hydrophobic field descriptor $\mathrm{H}_{-} 1007$ (0.3705,0.4404) has
positive range indicates that positive hydrophobic is favorable for activity at the R and Z position. Positive value of steric descriptor S_1130 (30.0000, 30.0000) showed that favourable and bulkier group is to prefer in that R and Z position triazole moiety.


Figure 6: Contribution plot of steric, electrostatic field and hydrophobic interactions 3D model 4.

3D model 4 showed electrostatic field descriptor E_790 and E_1005 $(-1.2756,-0.0455)$ with negative coefficient indicates that electron donating groups are favourable at the R and Z ring of triazoles moiety and more electronegative groups are preferred in that position.

Electron donating groups like amines, methoxy may increases the activity and electron withdrawing groups like $\mathrm{Br}, \mathrm{Cl}$ may significantly decrease the activity. The steric descriptor S_498 ( $-0.5820,-0.2431$ ) indicates less bulky group were required at R position. The hydrophobic descriptor H_1236(0.1093,0.4918) surrounding of ring indicate that hydrophobic substitution at the RÈ and $Z$ positions will decrease activity. The obtained pharmacophore model information shows that the five features used were two AroC feature
(aromatic), one HAc (hydrogen bond acceptor), and one negative ionizable ( NegC ) features (Figure 7). The average RMSD of the pharmacophore alignment of each two molecules is $0.4752 \AA$. Distance (59HDr-57HAc) $=4.7697$ Distance (59HDr-56NegC) $=7.3787 \AA$, Distance $(59 \mathrm{HDr} 16 \mathrm{O})=4.7697$ Distance $(56 \mathrm{NegC}$ $16 \mathrm{O})=3.4608 \AA$, Distance $(57 \mathrm{HAc} 33 \mathrm{C})=3.8406 \AA$, Distance $(57 \mathrm{HAc} 9 \mathrm{C})=4.5775 \AA$, Distance $(16 \mathrm{O} 22 \mathrm{C})=4.5921 \AA$, Distance $(56 \mathrm{NegC} 22 \mathrm{C})=4.7913 \AA$, Distance $(22 \mathrm{C} 59 \mathrm{HDr})=4.3521 \AA$.


Figure 7: Distance based pharmacophore model.

## 5. Conclusion

The combined QSAR analysis provides useful insight into the structural basic moiety for the series of derivatives as to improve their potency 3,4,5-trisubstituted $4 \mathrm{H}-1,2,4$-triazoles and a related series of 3 H -imidazo [1,2-b] [1,2,4] triazoles angiotensin II receptor. 2D-QSAR model was found that properties like polar surface area, T_2_F_4, T_C_O_1, and hydrogen donor count contributes around the moiety to increase activity whereas 3DQSAR model shows that substitution of less bulky, hydrophobic, electropositive and electronegative substitutions are preferable for better antihypertensive activity. In models shows the bulky, electron withdrawing, substituents at the chain of $\mathrm{R}^{!}$and Z position would be favourable. Furthermore, these results would be of great value in optimizing the discovery of new candidate antihypertensive drugs in the future before their synthesis.

## Acknowledgements

The author wishes to express gratitude to VLife Science Technologies Pvt. Ltd for providing the software for the study.

## Conflict of interest

The authors declare no conflicts of interest relevant to this article.

## References

Ajmani, S.; Jhadav, K. and Kulkarni, S.A. (2006). Three-dimensional qsar using the k -nearest neighbor method and its interpretation. J. Chem. Inf. Mod., 46:24-31.

Ashton,W.T.; Cantone, C.L.; Chang, L.L.; Hutchins, S.M.; Strelitz, R.A.; MacCoss ,M.; Chang, R.S.;Lotti, V.J.;Faust, K.A.; Chen, T.B.; Bunting,P.; Schorn,T.W.; Salah D. Kivlighn, S.D.; Peter K. S. and Sieglt, P.K.S. (1993) . Nonpeptide angiotensin II antagonists derived from $4 \mathrm{H}-1,2,4$-triazoles and $3 \mathrm{H}-$ imidazo [1,2-b][1,2,4] triazoles. J. Med. Chem., 36(5):591-609.

Bumpus, F.M.; Catt, K.J.; Chiu, A.T.; DeGasparo, M.; Goodfriend, T.; Husain, A.; Peach, M.J.; Taylor, D.G. and Timmermans, P.B. (1991). Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension, 17:720-721.

Clark, M.; Cramer, R.D. III and Van, O.N. (1989). Validation of the general purpose tripos 5.2 force field. J. Comput. Chem., 10:982-1012.
Cernes, R.; Mashavi, M. and Zimlichman, R. (2011). Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vasc. Health. Risk. Manag., 7:749-759.
Golbraikh, A. and Tropsha, A. (2002). Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. J. Comput. Aided. Mol. Des., 16:357-369.

Gute, B.D. and Basak, S.C. (1997). Predicting acute toxicity $\left(\mathrm{LC}_{50}\right)$ of benzene derivatives using theoretical molecular descriptors: A hierarchical QSAR approach. SAR. QSAR. Environ. Res., 7:117-131

Halgren, T.A. (1996). Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. J. Comp. Chem., 17:520-552.

Hellberg, S.; Sjostrom, M.; Skagerberg, B. and Wold, S. (1987). Peptide quantitative structure-activity relationships, a multivariate approach. J. Med. Chem., 30(7):1126-1135.
Hernández-Hernández, R.; Sosa-Canache, B.; Velasco, M.; Armas-Hernández, M.J.; Armas-Padilla, M.C. and Cammarata, R.(2002). Angiotensin II receptor antagonists role in arterial hypertension. J. Hum. Hypertens., 16(1): S93-99.

Karnik, S.S.;Unal, H.; Kemp, J.R.; Tirupula, K.C.; Eguchi, S.; Vanderheyden, P.M and Thomas, W.G.(2015). International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin receptors: Interpreters of pathophysiological angiotensinergic stimuli. Pharmacol. Rev., 67:754-819.

Maggioni, A.P.(2006). Efficacy of angiotensin receptor blockers in cardiovascular disease. Cardiovasc. Drugs. Ther., 20(4):295-308.

Schneider, G. (2011). Computational medicinal chemistry. Future. Med. Chem., 3(4): 393-394.

Sharma, M.C. (2015). Comparative pharmacophore modeling and QSAR studies for structural requirements of some substituted 2aminopyridines derivatives as inhibitors nitric oxide synthases. Interdiscip. Sci. Comput. Life. Sci.,7(2):100-112.

Sharma, M.C.; Sharma, S.; Sharma, P. and Kumar, A. (2014). Pharmacophore and QSAR modeling of some structurally diverse azaaurones derivatives as antimalarial activity. Med.Chem. Res., 23(1):181198.

VLife, MDS 3.5 (2010). Molecular design suite. Vlife Sciences Technologies Pvt. Ltd., Pune.

Mukesh Chandra Sharma (2023). Exploring the molecular structural requirements of 3, 4, 5-trisubstituted triazoles and imidazotriazole analogues as angiotensin II receptor using molecular modeling approach. J. Phytonanotech. Pharmaceut. Sci., 3(3):42-52. http://dx.doi.org/10.54085/jpps.2023.3.3.5


[^0]:    Corresponding author: Dr. Mukesh Chandra Sharma
    Assistant Professor, School of Pharmacy, Devi Ahilya Vishwavidyalaya, Takshila Campus, Indore-452001, Madhya Pradesh, India
    E-mail: drmukeshcsharma@gmail.com
    Tel.: +91-9826372944

